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Abstract: The threat of antimicrobial resistance has global health and economic consequences.
Medical strategies to reduce unnecessary antibiotic prescribing, to conserve the effectiveness of current
antimicrobials in the long term, inevitably result in short-term costs to health care providers.
Economic evaluations of health care interventions therefore need to consider the short-term costs
of interventions, to gain future benefits. This represents a challenge for health economists, not only
in terms of the most appropriate methods for evaluation, but also in attributing the potential budget
impact over time and considering health impacts on future populations. This commentary discusses
the challenge of accurately capturing the cost-effectiveness of health care interventions aimed at tackling
antimicrobial resistance. We reflect on methods to capture and incorporate the costs and health outcomes
associated with antimicrobial resistance, the appropriateness of the quality-adjusted-life year (QALY),
individual time preferences, and perspectives in economic evaluation.
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1. Introduction
Antimicrobial resistance encapsulates the loss of effectiveness of any anti-infective medicine,
including antiviral, antifungal, antibacterial, and antiparasitic medicines [1,2]. The threat of antimicrobial
resistance has global health and economic consequences; resistant infections are responsible for an
estimated 700,000 deaths annually worldwide which, if no action is taken, could result in a cumulative
cost of $100 trillion by 2050 [3]. Urgent threats include Clostridioides difficile, carbapenem-resistant
Enterobacteriaceae (CRE), and drug-resistant Neisseria gonorrhoeae [4]. The current rate of Clostridioides
difficile infection in the United States (US) alone is 500,000 cases and 15,000 deaths per year. The urgency
of addressing antimicrobial resistance is recognised widely [4,5], and a range of containing strategies have
been implemented, including antimicrobial stewardship, which has become a central aspect of delivering
safe and effective health care [6]. Antimicrobial stewardship involves a coordinated approach to promote
and monitor the judicious use of antimicrobials to preserve their future effectiveness [6]. The UK’s
five-year action plan outlines three key targets for tackling antimicrobial resistance: (i) reducing need
and unintentional exposure, (ii) optimizing use, and (iii) investing in innovation, supply, and access [3].
A key strategy to achieve these aims includes more appropriate prescribing, which includes reducing
unnecessary antibiotic prescribing [7–10]. Not only is unnecessary antibiotic prescribing costly for little or
no therapeutic benefit, it places patients at risk of adverse effects [8,11] and contributes to the development
of antibiotic resistance [7–10]. The potential for improved health outcomes and lower costs are easily
recognised; however, health care strategies may also include trade-offs between short-term outcomes and
long-term gains, for example, not using the most effective anti-infective medicine, in order to preserve
future effectiveness. This represents a shift of focus of evaluation, from clinical decision making
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for an individual patient in the present, to a longer-term (intergenerational) public health agenda.
Similarly, there has been a shift of focus in the pharmaceutical industry, with strategies incentivizing
the pharmaceutical industry to develop new drugs, using funding mechanisms not linked to volume [3].
Economic evidence is central to understanding the value of competing health care strategies
to lessen the probability of resistance development [12,13]. Interventions or services are typically
evaluated using standard methods of health technology assessment, including cost-effectiveness
or cost-utility analyses. Economic evaluations inform judgements on whether the value of additional
health benefits exceed the opportunity cost; where opportunity cost is the next best alterative foregone.
As conventionally applied, health benefits relate to the effectiveness of interventions in relation
to managing infections less any adverse effects, which are typically confined to adverse drug reactions.
However, the application of such methods in the context of antimicrobial resistance poses several
unique methodological challenges, not least in quantifying the costs and externality effects (impacts on
other patients) of future reductions in antimicrobial effectiveness (Table 1).
Table 1. Examples of challenges for the economic evaluation of health care strategies to contain
antimicrobial resistance.
Item Example of Challenges Recommendations
Population
Population extends beyond those receiving
the intervention. This is also likely to extend across
health technology agency (HTA) boundaries.
Where appropriate, extend the population
beyond the cohort receiving
the intervention and consider other/future
patients who become infected by a resistant
pathogen, or who have not experienced
resistant infection but receive alternative
agents due to increased resistance
of common pathogens.
Clinical
Adequate measurement of the expected rate
of growth of antimicrobial resistance and
associated outcomes over time. Clinical parameters
in the present are more easily captured than those
associated with future global consequences.
Use both empirical data and secondary data
to forecast long-term clinical consequences.
Ensure appropriate assessment
of uncertainty.
Costs
Resource implications most likely to be short-term.
Difficult to capture long-term resource use and
the cost of negative externalities. Cost of health
care intervention impacts different budgets
to the return, e.g., primary care cost in short-term,
for long-term secondary care gains.
Application of robust resource use data
collection methods [14]. Include costs
of treating patients not receiving
the intervention (see population).
Use threshold analysis as an alternative
to specifying attaching an actual cost
to antimicrobial resistance.
Health outcomes
Health states associated with acute infection may
be perceived as transient, which limits the validity
of trade-off exercises typically used for utility
valuation. Utility measures, such as the EQ-5D,
measure health “today” and fail to capture
the value (utility) associated with future health
gains.
Cautious interpretation
of quality-adjusted-life year (QALY) gains.
Consider alternative or multiple
frameworks for analysis,
e.g., disability-adjusted-life year (DALYs)
to assess global burden, cost-benefit
analysis, using contingent valuation.
Where appropriate include the disutility
for patients with resistant infection
and the disutility of alternative agents.
Perspective
Economic evaluations of health care intervention
are often restricted to direct health effects and costs
with the health technology program considering
the evidence. Antimicrobial resistance is a societal
issue and extends beyond individual
HTA jurisdictions.
Consider a societal perspective to reflect
the true range of costs and outcomes.
Acknowledge the limitations of HTA
by individual agencies.
Time horizon
Evaluations often adopt inadequate time horizons.
Time preference may be paradoxical
for antimicrobial consumption. Costs and
outcomes extend to future generations.
Adopt a lifetime horizon of analysis,
use appropriate discounting rates,
and conduct empirical research on time
preferences for antimicrobial preferences.
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2. Challenges
2.1. Capturing the Benefits of Strategies to Contain Antimicrobial Resistance
How best to assess the value of any intervention to reduce antimicrobial resistance is a methodological
challenge, which requires adequate measurement of the expected rate of growth of antimicrobial resistance
and associated outcomes over time [15]. Economic evaluation of health care strategies to reduce antibiotic
prescribing, for instance, ought to value their impact on antimicrobial resistance. Most economic evaluations
in this area, however, fail to consider the costs and outcomes relating to antimicrobial resistance—or
where they have, consideration has been restricted to projected financial costs and was not reflective
of population health [16,17]. In order to achieve this, data are required on the long-term health outcomes
of both current patients and future cohorts of patients who may be prescribed antimicrobial therapy
in the future. This includes the health outcome of patients who become infected by a resistant pathogen,
or who have not experienced resistant infection but receive alternative agents due to increased resistance
of common pathogens. The disutility of potentially less effective treatment represents an important
economic parameter that is required in addition to the capturing the more obvious morbidity and mortality
associated with short-term health outcomes of the patient presenting with an infection.
Measure of Health Outcome
Economic evaluations of health care interventions to tackle antimicrobial resistance may consider
different measures of health outcomes, ranging from the number of prescriptions avoided, to years of life
gained and quality-adjusted-life years (QALYs). Cost-utility analyses, which yield incremental costs
per QALY gained, measure value in terms of health utility and survival. Utility represents the value or
desirability of a given health state, most typically based on indirect, multi-attribute, preference-based
measures, such as the EQ-5D [18,19]. The appropriateness of QALYs for use in evaluation of acute
conditions, such as respiratory tract infections, a common focus of intervention aimed at tacking
antimicrobial resistance, has both measurement and evaluation problems. Health state utilities
used to calculate the QALY are typically elicited using trade-off exercises, and the issue with acute
infection is that when trading quality and quantity of life, the ill-health state may be perceived as
transient, thus questioning the reliability of this method [20]. Furthermore, health care strategies
to contain antimicrobial resistance—by design—are only unlikely to concern the outcomes of today.
The valuation of future health outcomes is also important and represents a challenge for health
economists. An alternative evaluative framework may be required to capture the complexity of health
outcomes over time.
The disability-adjusted-life year (DALY) represents an alternative health index used in cost-effectiveness
analyses. The DALY captures the number of healthy years lost, by incorporating reduction in life expectancy
with years lost to disability; as such health care interventions seek to avert the DALY (as opposed to increasing
the QALY). The DALY provides an estimate of the burden of disease, such as infectious diseases, that is
useful in global health prioritization. Cassini and colleagues reported the DALYs caused by five infections
with antibiotic-resistant bacteria across populations in Europe and found this to be substantive compare
to other infectious diseases [21]. From a global health perspective, the DALY is an oft-used measure that
can be utilised in economic evaluations.
Cost-benefit analysis (CBA) is an approach to economic evaluation that places a monetary
valuation on the consequences as well as the costs of interventions. This may be achieved using
methods such as willingness to pay, which has been suggested as an alternative to the QALY when
evaluating acute disease [20]. The willingness to pay method is based on contingent valuation to elicit
monetary value for items not typically traded, such as health, and therefore accounts for both health
and non-health effects. Whilst this is considered more comprehensive, in many jurisdictions patients
may be unfamiliar with purchasing health care directly, and this may have an impact on the reliability
of the methods. A further challenge is the potential association with ability to pay, based on income and
wealth. In the context of health care strategies to tackle antimicrobial resistance, however, cost-benefit
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analysis offers a feasible method for capturing the cost of the negative externalities, on a global scale,
to represent the true value future benefits. Where applied with robust formative work, there is potential
for this method to be used to elicit individuals’ willingness to pay to avoid an illness (resistant infection)
or obtain the benefits of a future treatment.
2.2. Perspective
Prior to conducting any economic valuation, the perspective needs to be defined [22]. The perspective
of the valuation, e.g., whether it is conducted from the point of view of the patient, health care payer,
or society, will determine the costs and outcomes that need to be included in the analysis. In the UK,
the National Institute for Health and Care Excellence (NICE) recommends the perspective on outcomes
should be all direct health effects, whether for patients or other people; and the perspective adopted on
costs within its Technology Appraisal programme should be that of the National Health Service (NHS) and
personal and social services (PSS) [23]. Benefits are the assigned general population’s valuation of health
outcome (obtained from surveys), and costs include the cost of treatment and associated health service
resource use (e.g., GP visits, hospitalisation, etc.). Whilst this provides a reference case for comparison
of different health technologies, such Technology Appraisals consider individual patients or cohorts
of patients, whereas antimicrobial resistance should consider populations. Evaluation of containment
strategies may necessitate a broader perspective, and evidence in other areas suggests that assessment
of the same strategy from different perspectives can arrive at different conclusions [24].
The broadest perspective adopted in economic evaluation is the societal perspective. This should
reflect the full range of social opportunity costs associated with different interventions [22], for example,
productivity losses due to patients’ inability to work. However, there is a paucity of evidence on
the long-term indirect impact of antimicrobial resistance on costs and outcomes [25], and this represents
a significant challenge for health economists evaluating containment strategies. Economic evaluations
with restrictive perspectives have potential to overestimate the value of interventions or services.
Where the perspective for costs is limited to hospital or health service, indirect costs to current and future
patients, such as working days lost due to resistant infection, or treatment toxicity, fail to be captured.
To fully assess the cost-effectiveness of strategies to contain antimicrobial resistance and to avoid
the inefficient allocation of scarce health service resources, decision makers require economic
evaluations that incorporate costs and outcomes beyond the patient and hospital and consider
the full ramification of antimicrobial resistance. Defining the “society” then becomes a challenge within
itself, as antimicrobial resistance impacts populations that extends across jurisdictions. Adoption of a
global multiagency perspective represents new territory and a limitation of conventional health
technology assessment (HTA) and health-economic approaches. In the absence of long-term data,
economists have taken a pragmatic approach; for example, our evaluation of C-reactive protein testing
to guide antibiotic prescribing for lower respiratory tract infection in Wales, included a sensitivity
analysis of the cost of the long term global cost of antibiotic resistance [17]. A challenge for future
economic evaluation is to incorporate more robust measurement and modelling of longer-term indirect
costs and outcomes—that go beyond today’s cohorts of patients to consider the population of tomorrow.
2.3. Capturing the Long-Term Costs of Antimicrobial Resistance
The resource implications of antimicrobial resistance are most likely to accumulate in the long-term.
Short-term, direct health effects may only include the effect of the intervention on the affected patient;
however, longer-term effects on both the patient and others are more likely. It is therefore important
that all costs are captured and incorporated into economic evaluations across adequate time-horizons.
Whilst interventions to reduce unnecessary prescribing in a clinical setting may represent a short
time horizon, e.g., prescribing outcomes and re-consultation over 28-days, the longer-term effects
of unnecessary antibiotic prescribing extend to current and future patients’ lifetimes [10,26]. Initially,
resource use and costs associated with interventions that aim to contain resistance would typically be
captured using health records and/or patient reports in the short-term. Estimating long-term direct
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and indirect cost and the cost consequences to others, however, may present more of a challenge.
The cost impact has potential to go beyond the lifetime horizon of the patient and impact the population
of tomorrow, and in some situations the product life-cycle [27] may be more relevant than the life time
of the patients being treated.
Where long-term costs have been considered in existing economic evaluations, these have relied
on estimates of per-prescription costs of antimicrobial resistance based on rudimentary calculations
of the global costs of resistance divided by the annual number of prescriptions in each geographic
region [16]. Oppong et al. 2013 [16], reported three estimates for the cost of antibiotic resistance,
based on the annual cost of resistance in the US ($55 billion) [28], the cost of multidrug resistance
in the European Union (EU) (€1.5 billion) [29], and the cost of global resistance over a 35-year period
(US$2.8 trillion annually) [5]. This method assumes that antibiotic prescribing is the main cause
of resistance, but whilst more robust estimates are required, it is widely acknowledged that this would
require complex modelling methods [15]. Robust estimates of other long-term health conditions, such
as increased risk of Clostridioides difficile infection, also require consideration. Indirect costs are also
often difficult to estimate, as they may bias against people who are not in employment and may
fluctuate over time.
A further challenge is that both direct and indirect costs may be attributable to different systems
and payers at different time points. For example, even when restricting analysis to direct health service
costs, the initial outlay for point of care C-reactive protein testing to avoid unnecessary antibiotic
prescribing may be borne by a local health service provider; however, the longer-term cost savings are
likely to be at a secondary level. Data collection should not be restricted to a single source, such as
primary care databases, but should utilise appropriate methods (e.g., self-report, hospital episode data)
to collect comprehensive data reflective of all costs incurred [14].
2.4. Time Preference
An individual’s time preference represents the extent to which they are willing to trade between
short-term costs and/or benefits and long-term costs and/or benefits, attributable with a health-related
behaviour, such as the consumption of antimicrobials. The time preference rate (discount rate)
quantifies the difference between the perceived value of future outcomes relative to more immediate
ones. Individuals with lower time preference rates have a higher value for future utility and therefore
discount the future less; and conversely, individuals with higher time preference rates have a lower
value for future utility and so require greater future reward for their behaviour. Time preference
rates for health are typically between 3–6% per annum [30]. In the UK a consistent societal discount
rate of 3.5% per annum is applied as recommended in guidance issued by HM Treasury on how
to appraise policies, programs, and projects [31]. Variation in the choice of discount rate has a marked
effect on studies with long time horizons and is therefore an important consideration for evaluations
of strategies aimed to contain resistance—an issue defined by long-term impacts. Given the future
value of antibiotics, a lower (zero or perhaps even negative in some circumstances) discount rate may
be more relevant for health outcomes [32]. This issue also applies to vaccination, where differential
discounting in model-based cost-effectiveness evaluations is being explored [33]. Empirical evidence
on time preference rates can be estimated using stated preference techniques that rely on hypothetical
scenarios [34]. Participants are typically required to imagine a health state and choose between future
outcomes related to that hypothetical health state; this method would generate empirical evidence on
individuals time preferences to inform future economic evaluations. A further challenge that will need
to be addressed is that in the context of antimicrobial resistance, the future health state to be valued is
not that of the respondent but is more likely to be the future health of others. Sensitive analysis using
a range of discount rates is recommended.
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3. Conclusions
Ascertaining the most clinically and cost-effective interventions and services to reduce
antimicrobial resistance will require a multifaceted approach, from incentivizing pharmaceutical
companies to co-production of patient-centred acceptable interventions that maximise the utility of both
patients and society. Economic evidence is central to understanding the value of competing strategies
to lessen the probability of resistance development, although the application of such methods poses
several methodological challenges. When assessment and interpreting the results of existing economic
evaluations of health care interventions in the context of antimicrobial resistance, careful consideration
is required, of the perspective, costs, and externality effects (impacts on other patients) of future
reductions in antimicrobial effectiveness. We have presented just some of the challenges of accurately
estimating the cost-effectiveness of interventions to tackle antimicrobial resistance. Further research is
required to capture the effects of antimicrobial resistance in economic evaluations to reflect the value
of preserving effective medicines for future use. This requires appropriate consideration of the wider
externalities and methodological approaches which differ from standard “reference” case of NICE and
other HTA organizations.
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